AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05749601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The influence of patellofemoral morphology in the radiological severity of knee osteoarthritis
Description: Highlighting the influence of distal femoral torsion angle, patellofemoral congruence angle and sulcus angle, in KOA severity under the influence of sex and age.
Study NCT05749601 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The influence of patellofemoral morphology in the radiological severity of knee osteoarthritis
Description: Highlighting the influence of distal femoral torsion angle, patellofemoral congruence angle and sulcus angle, in KOA severity under the influence of sex and age.
Study NCT05749601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The influence of ROS from the synovial fluid on the severity of KOA
Description: Highlighting the influence of ROS from the synovial fluid in KOA severity under the influence of some biochemicals blood constants.
Study NCT05749601 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The influence of ROS from the synovial fluid on the severity of KOA
Description: Highlighting the influence of ROS from the synovial fluid in KOA severity under the influence of some biochemicals blood constants.
Study NCT06400966 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training method
Description: Jigsaw Technique
Study NCT05633992 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23
Description: Sterile 0.5 mL solution in prefilled syringe containing 25 μg of each PnPs antigen 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
Study NCT04751461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P0211220, a 1.8% nicotine ENDS product
Study NCT06321978 — intervention group
Intervention type: DEVICE
Intervention: Mepilex Border Flex
Description: Usage of Mepilex Border Flex according to intended use and standard of care.
Study NCT05730790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive-motor dual task training (DTT)
Description: For session 1 to 3, the training comprises of 4 cycles of the following: 2 min dual tasking, 2 min rest, 2 min dual tasking, 2 min rest. For session 4 to 6, the training comprises of 4 cycles of the following: 2.5 min dual tasking, 1.5 min rest, 2.5 min dual tasking, 1.5 min rest. For session 7 to 14, the training comprises of 4 cycles of the following: 3 min dual tasking, 1 min rest, 3 min dual tasking, 1 min rest. The treadmill speed is maintained at 40%, 50% and 60% of participant's original gait speed at session 1 to 3, 4 to 6, and 7 to 14 respectively.~There are 10 levels in the VR game. Participant will start at level 1 of VR game at session 1 and can progress to the next level at the subsequent session if game percentage > 80%.
Study NCT05730790 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive single task training (CSTT)
Description: For session 1 to 3, the training comprises of 4 cycles of the following: 2 min VR gaming, 2 min rest, 2 min VR gaming and 2 min rest. For session 4 to 6, the training comprises of 4 cycles of the following: 2.5 min VR gaming, 1.5 min rest, 2.5 min VR gaming and 1.5 min rest. For session 7 to 14, the training comprises of 4 cycles of the following: 3 min VR gaming, 1 min rest, 3 min VR gaming and 1 min rest.~There are 10 levels in the VR game. Participant will start at level 1 of VR game at session 1 and can progress to the next level at the subsequent session if game percentage > 80%.
Study NCT05730790 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor single task training (MSTT)
Description: For session 1 to 3, the training comprises of 4 cycles of the following: 8 min treadmill walking at 40% of participant's original gait speed followed by 2 min rest. For session 4 to 6, the training comprises of 4 cycles of the following: 8 min treadmill walking at 50% of participant's original gait speed followed by 2 min rest. For session 7 to 14, the training comprises of 4 cycles of the following: 8 min treadmill walking at 60% of the participant's original gait speed followed by 2 min rest.
Study NCT04751461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: P0211820, a 1.8% nicotine ENDS product
Study NCT06201975 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Thyme honey
Description: Thyme honey will be delivered to the sites until overflows using a syringe with plastic catheter of cannula 20 g (B Braun) attached to it. Patients will be reviewed at 6 weeks to re-evaluate the clinical periodontal parameters
Study NCT06201975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thyme honey
Description: Thyme honey will be delivered to the sites until overflows using a syringe with plastic catheter of cannula 20 g (B Braun) attached to it. Patients will be reviewed at 6 weeks to re-evaluate the clinical periodontal parameters
Study NCT04751461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: P0213417, a 2.4% nicotine ENDS product
Study NCT05489263 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05382793 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: No iodine
Study NCT05382793 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iodide (150 μg/day)
Description: A single oral tablet once daily for five days providing 150 μg iodine as potassium iodide
Study NCT05382793 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iodine (300 μg/day)
Description: Two oral tablets (150 μg + 150 μg) daily for five days providing 300 μg iodine as potassium iodide
Study NCT05697237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrelizumab
Description: Carrelizumab 200mg/3 weeks
Study NCT05697237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solfantinib
Description: Solfantinib 300mg/d
Study NCT05068739 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PA-EMR
Description: Standard oval-shaped, braided wire polypectomy snare with 10 mm or 20 mm loop diameter will be used. With the duodenoscope in a semi-long position, the tip of the snare will be anchored just below the transverse fold of the ampulla and opened above-downwards fashion until the orifice will be seen. The orifice will be strictly preserved to avoid the risk of PEP and approximately the upper two-thirds of the ampullary mound will be grabbed by the snare. The direction and the depth will be controlled by combined movements of the elevator and wheels of the duodenoscope. After removal of the mucosa, the wall of choledochus will be seen clearly and standard wire-guided cannulation (WGC) will be performed. If cannulation can not be achieved with WGC, an additional incision will be performed to the wall of the choledochus with a needle knife.
Study NCT05068739 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NKF
Description: The needle knife will be placed at the junction of the upper one-third and lower two-thirds of the papillary roof (bulging portion). Minimal, superficial incisions will be made in the 11-12 o'clock direction. The length of the fistulotomy will be at the endoscopist's discretion, depending on the shape of the papilla. The cut will be extended until bile juice, the pinkish bile duct mucosa, and/or the bulging of the white sphincter of the Oddi's muscle is visible.
Study NCT06436963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: narrative medicine training combined with CBL training
Description: The experimental group received narrative medicine training combined with CBL training.
Study NCT06436963 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBL training
Description: The control group received normal CBL training.
Study NCT05545241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback + BART/EEG
Description: 10 sessions of emotional neurofeedback (max of 2 sessions per week and max of 10 weeks).~Before (Baseline, Day 0) and at the study completion (after 10 neurofeedback sessions, Week 5), a EEG record is realized during the BART, assessing risk-taking behavior.
Study NCT05545241 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: BART/EEG only
Description: only the twice EEG record are realized during the BART, assessing risk-taking behavior (every corresponding to the pre and post-neurofeedback evaluations in arm I)
Study NCT05196984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GENUS device (Active Settings)
Description: Participants in the active condition within the Down Syndrome participant group and the Cognitively Normal Control group will use the GENUS device configured to active 40Hz settings for 30-60 minutes.
Study NCT05196984 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GENUS device (Sham Settings)
Description: Participants in the control condition within the Down Syndrome participant group and the Cognitively Normal Control group will use the GENUS device configured to sham settings for 30-60 minutes.
Study NCT06447662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07934040
Description: panKRAS inhibitor
Study NCT06447662 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy (antimetabolite)
Study NCT06447662 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Taxane-type Chemotherapy
Study NCT06447662 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Monoclonal Antibody (EGFR Inhibitor)
Study NCT06447662 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Part of FOLFOX chemotherapy regimen~cytotoxic chemotherapy (antimetabolite and pyrimidine analog)
Study NCT06447662 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Part of FOLFOX Chemotherapy Regimen~platinum based compound (alkylating agent)
Study NCT06447662 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Part of FOLFOX chemotherapy regimen~Folic Acid Analog
Study NCT06447662 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: VEG-F inhibitor
Study NCT06447662 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: immune checkpoint inhibitor (PD-1 inhibitor)
Study NCT06447662 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Can be used in Platinum-based Chemotherapy regimen~Antimetabolite
Study NCT06447662 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Can be used as part of Platinum-based chemotherapy regimen~Platinum-based antineoplastic (alkylating agent)
Study NCT06447662 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Can be used in Platinum-based chemotherapy regimen~Taxane
Study NCT06447662 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Can be used as part of a platinum-based chemotherapy regimen~platinum containing compound (alkylating agent)
Study NCT06370871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigimadlin
Description: Brigimadlin
Study NCT06370871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezabenlimab
Description: Ezabenlimab
Study NCT06370871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Solution for infusion
Study NCT06370871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Solution for infusion
Study NCT06307756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music group
Description: Mothers will be informed about the application before the procedure. Mothers who agree to participate in the study will be asked to listen to music that relaxes them for 20 minutes a day for 4 days. The mothers' state anxiety levels and milk quantities will be evaluated before starting the application and every day during the application. Mothers' anxiety levels will be evaluated with the State Anxiety Inventory. Mothers' anxiety levels and milk quantities will be evaluated every day at 11.45 when they come to the NICU to express milk.
Study NCT04967547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-care PD ability assessment form
Description: Subjects will be evaluated using the self-care PD feasibility assessment tool within 7 days after randomization. The evaluation results will be provided to the patient on the same day
Study NCT04967547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education on renal replacement therapy and dialysis
Study NCT04967547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Education on renal replacement therapy and dialysis
Study NCT05431023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: Lactoferrin binds to and blocks glycosaminoglycan viral receptors, especially heparan sulfate (HS). The binding of LF and HS prevents the first contact between virus and host cell and therefore prevents the infection
Study NCT05431023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pneumonia treatment
Description: Antibiotics for pneumonia
Study NCT06112158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Intervention
Description: The BSE training program for the early diagnosis of breast cancer will be offered to students in two ways: face-to-face and via web support.~Content of training Session 1: Topics such as the structure of the breast, the definition of breast cancer, its prevalence, risk factors and symptoms Session 2: Teaching the importance of early diagnosis in breast cancer, the importance and benefits of BSE, the technique of performing BSE, the obstacles to the application of BSE.~Session 3: Teaching the risk factors that cause breast cancer. Session 4: Discussion of case reports of patients diagnosed with breast cancer. Supporting education with web support
Study NCT05848492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Fluconazole will be given for prevention of invasive candidiasis in preterm and very low birthweight babies.
Study NCT05848492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.9% Saline 2cc intravenous will be given to preterm babies in placebo group.
Study NCT06027918 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular brachial plexus block
Description: In the application of infraclavicular brachial plexus blocks (coracoid approach); 1.5mg/kg dose of bupivacaine and 1mg/kg lidocaine mixture will be applied around the axillary artery in the 6 o'clock position under US guidance.
Study NCT04829032 — intervention group
Intervention type: PROCEDURE
Intervention: Hartmann's procedure
Description: Hartmann's procedure
Study NCT04721119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Infiltration Anesthetic
Description: For the local infiltration anesthetic, patients will receive 20 cc of 0.5% ropivacaine, by intra-articular injection performed by the surgeon. The injection is done at the end of the surgical procedure, after suturing the incision.
Study NCT04721119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Infiltration Anesthetic + Adductor Canal Block
Description: For the local infiltration anesthetic, patients will receive 20 cc of 0.25% ropivacaine, by intra-articular injection performed by the surgeon. The injection is done at the end of the surgical procedure, after suturing the incision. For the adductor canal block, patients will receive 20 cc of 0.25% ropivicaine, through injection performed by the anesthesiologist. The injection is done under the sartorius muscle, in mid-thigh, using ultrasound guidance.
Study NCT05665972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mandala coloring
Description: Each participant will be given 12 colored felt-tip pen paint sets and 12 mandala coloring pages by the researchers. Participants will be asked to dye for 3 menstrual cycles, 14 days before the start of menstruation, 1 day a week, at any time of the day and for an average of 20-30 minutes each time.
Study NCT04977297 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Move to Music Intervention (M2M)
Description: The move to music (M2M) intervention pairs exercise with only music (no video), providing only audio stimulation. The intervention will be provided via an audio playlist that can be played on a phone, tablet, or computer. Each session lasts 10-15 minutes.
Study NCT06159556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peanut intake
Description: Participants will consume 2 ounces of peanuts/peanut butter for 12 weeks
Study NCT06078709 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06078709 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and PET/CT scan
Study NCT06078709 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound
Description: Undergo EUS
Study NCT06078709 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: Undergo EGD
Study NCT06078709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT06078709 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy
Study NCT06078709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT06078709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT06078709 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET and PET/CT scan
Study NCT06078709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT06078709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT05111600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplantation
Description: Implantation of autologous cultured grafts containing genetically modified stem cells for restoration of functional skin on pre-selected areas
Study NCT06376565 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard care
Study NCT06376565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Complete clinic EHR interventions
Study NCT06376565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Receive scheduling reminders
Study NCT06376565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Receive reminders and pending EHR orders
Study NCT06376565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Complete interview
Study NCT06376565 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Ancillary studies
Study NCT06489574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracic epidural with dexmedetomidine in patients undergoing thoracotomy surgery
Description: A thoracic epidural catheter will be inserted at the T6- T7 intervertebral space, with the patient in the sitting position with standard aseptic precautions using an 18-G Touhy needle via a midline or paramedian approach with a loss of resistance method. A test dose of 3 ml of 2% lignocaine with adrenaline 5 µ/ml will be administered.~For thoracic surgery the sensory dermatome blockade needs to cover the incision and intercostal drains and may extend from T4 to T8.~The epidural drug will be administered according to the group allocation over a period of 10 minutes as follows:~Group A:~Patients will receive 50 μg dexmedetomidine with 10 ml of 0.125% bupivacaine followed by a continuous infusion of (10 ml bupivacaine + 25 μg dexmedetomidine + 39 ml saline with rate of 5 ml per hour).
Study NCT05742269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 89Zr-atezolizumab PET/CT
Description: All patients undergo a 89Zr-atezolizumab PET/CT. Allocation to chemotherapy + atezolizumab in case of a PD-L1 positive tumor (on IHC and/or PET)
Study NCT04977297 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move to Music -Video (M2M-V) Intervention
Description: The move to music video (M2M-V) intervention pairs exercise with both music and video, thus providing both audio and visual stimulation. The intervention will be provided via an audio and video playlist that can be played on a phone, tablet, or computer. Each session lasts 10-15 minutes.
Study NCT04794608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYPNO VR® device
Description: The HYPNO VR® device is a software application of medical hypnosis in the treatment of pain and anxiety. It is associated with equipment: a virtual reality headset and a headphone.~Before each session of hypnosis, the nursing staff offers patients the choices: visual universe, musical theme, male or female voice. The nursing staff selects the program, selects a duration of 20 minutes and presses start to start the medical hypnosis session in virtual reality.~After completing the hypnotic trance sequence, as in a classic session, the patient is brought back to the return and exit hypnosis phase under the supervision of the nursing staff.